Clinical Trial

Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.

Study acronym: LYMPHOVIR-IRCT
Recruiting
View on ClinicalTrials.gov →
Summary
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease. The study population was patients with chronic kidney disease.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-06-19; most recent amendment 2026-06-22.
Status change: Not Yet Recruiting → Recruiting 2024-12-12
Trial Details
NCT Number NCT06474169
Lead Sponsor Centre Hospitalier Régional d'Orléans
Conditions Chronic Kidney Diseases
Enrollment 100 participants
Start Date 2024-11-27
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-25